[Hepatorenal Syndrome]

Korean J Gastroenterol. 2023 Nov 25;82(5):224-232. doi: 10.4166/kjg.2023.108.
[Article in Korean]

Abstract

Hepatorenal syndrome (HRS) is a critical and potentially life-threatening complication of advanced liver disease, including cirrhosis. It is characterized by the development of renal dysfunction in the absence of underlying structural kidney pathology. The pathophysiology of HRS involves complex interactions between systemic and renal hemodynamics, neurohormonal imbalances, and the intricate role of vasoconstrictor substances. Understanding these mechanisms is crucial for the timely identification and management of HRS. The diagnosis of HRS is primarily clinical and relies on specific criteria that consider the exclusion of other causes of renal dysfunction. The management of HRS comprises two main approaches: vasoconstrictor therapy and albumin infusion, which aim to improve renal perfusion and mitigate the hyperdynamic circulation often seen in advanced liver disease. Additionally, strategies such as liver transplantation and renal replacement therapy are essential considerations based on individual patient characteristics and disease severity. This review article provides a comprehensive overview of hepatorenal syndrome, focusing on its pathophysiology, diagnostic criteria, and current management strategies.

Keywords: Acute kidney injury; Hepatorenal syndrome; Liver cirrhosis.

Publication types

  • English Abstract
  • Review

MeSH terms

  • Hepatorenal Syndrome* / diagnosis
  • Hepatorenal Syndrome* / etiology
  • Hepatorenal Syndrome* / therapy
  • Humans
  • Kidney
  • Liver Cirrhosis / complications
  • Liver Cirrhosis / diagnosis
  • Liver Cirrhosis / drug therapy
  • Liver Transplantation* / adverse effects
  • Vasoconstrictor Agents / therapeutic use

Substances

  • Vasoconstrictor Agents